You are here

First-in-class Arginase 2 inhibitory antibody

The Opportunity: 

In collaboration with Universities of Oxford and Leicester our CRUK-AstraZeneca Antibody Alliance Laboratory has developed a first-in-class, inhibitory antibody specific for human ARG2.

The Technology: 

Dysregulation of 2 isoforms of arginase, ARG1 and ARG2, has been linked to disorders associated with inflammation and immunity including cardiovascular and pulmonary diseases, renal diseases, cancer, response to infectious agents and neurovascular diseases.  In collaboration with Universities of Oxford and Leicester our CRUK-AstraZeneca Antibody Alliance Laboratory has developed a first in class, inhibitory antibody specific for human ARG2 and with favourable kinetics.  Patent protecting the antibody (and backup molecules) is available for licensing in oncology and/or non-oncology indications.